Related Experiment Videos
Corneal graft rejection: a new rabbit model and cyclosporin-A
Abstract:
In order to test the efficacy of topically applied cyclosporin-A in preventing corneal allograft rejection, existing rabbit models were modified to produce a new model in which the allograft reaction could be consistently initiated solely as a result of corneal transfer without any additional means of sensitisation. With this model, which reflects clinical corneal grafting more closely than many previous models, cyclosporin-A 1% drops applied to the recipient eye 5 times daily for 4 weeks inhibited corneal graft rejection. When cyclosporin-A 1% drops were applied to corneal allografts for 13 weeks, 44% of grafts remained clear 180 days after transplantation. No side effects were observed that could be attributed to topically applied cyclosporin-A.
Insights
Topical cyclosporin-A eye drops effectively prevent corneal allograft rejection in a new rabbit model. This immunosuppressive treatment showed no adverse effects, offering promise for clinical corneal transplantation.
Area of Science:
- Ophthalmology
- Immunology
- Transplantation Biology
Background:
- Corneal allograft rejection remains a significant challenge in transplantation.
- Existing animal models often lack the specificity to isolate rejection causes.
- A refined rabbit model is needed to accurately assess immunosuppressive therapies.
Purpose of the Study:
- To evaluate the efficacy of topical cyclosporin-A in preventing corneal allograft rejection.
- To establish a novel rabbit model for consistent allograft rejection initiation.
- To assess the safety profile of topically applied cyclosporin-A.
Main Methods:
- Modification of existing rabbit models to create a new system for consistent corneal allograft rejection.
- Application of 1% cyclosporin-A eye drops to recipient eyes five times daily for four weeks.
- Long-term observation of graft survival and clarity for up to 180 days post-transplantation.
Main Results:
- Topical cyclosporin-A (1%) significantly inhibited corneal graft rejection when applied for four weeks.
- Extended treatment with cyclosporin-A drops for 13 weeks resulted in 44% of grafts remaining clear at 180 days.
- No observable side effects were associated with the topical administration of cyclosporin-A.
Conclusions:
- Topical cyclosporin-A is an effective prophylactic treatment against corneal allograft rejection.
- The developed rabbit model provides a reliable platform for studying corneal transplantation and immunosuppression.
- Cyclosporin-A demonstrates a favorable safety profile for topical ocular use in preventing graft rejection.